Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $2 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$2 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -511.7% |
| EBITDA | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -829.7% |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -830.1% |
| EPS Diluted | -0.28 | -0.31 | -0.64 | -1.37 |
| % Growth | 9.7% | 51.6% | 53.3% | – |
| Operating Cash Flow | -$2 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$0 | -$0 | -$0 |